UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (4) 4
life sciences & biomedicine (3) 3
lung cancer (3) 3
non-small cell lung carcinoma (3) 3
oncology (3) 3
small cell lung carcinoma (3) 3
tumors (3) 3
biomarkers (2) 2
cancer therapies (2) 2
chemotherapy (2) 2
drug dosages (2) 2
female (2) 2
humans (2) 2
male (2) 2
mutation (2) 2
patients (2) 2
[sdv.bc]life sciences [q-bio]/cellular biology (1) 1
[sdv]life sciences [q-bio] (1) 1
abridged index medicus (1) 1
acrylamid (1) 1
acyclovir (1) 1
adenocarcinoma (1) 1
administration, oral (1) 1
adult (1) 1
aged (1) 1
aged, 80 and over (1) 1
analysis (1) 1
antineoplastic agents, immunological (1) 1
antineoplastic agents, immunological - administration & dosage (1) 1
antineoplastic agents, immunological - adverse effects (1) 1
antineoplastic combined chemotherapy protocols (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
antisense therapy (1) 1
antiviral agents (1) 1
antiviral agents - therapeutic use (1) 1
apoptosis (1) 1
b7-h1 antigen (1) 1
b7-h1 antigen - metabolism (1) 1
carboplatin (1) 1
carcinoma, non-small-cell lung (1) 1
carcinoma, non-small-cell lung - drug therapy (1) 1
carcinoma, non-small-cell lung - metabolism (1) 1
carcinoma, non-small-cell lung - mortality (1) 1
cell adhesion & migration (1) 1
cell cycle (1) 1
cell proliferation (1) 1
cellular biology (1) 1
chemical synthesis (1) 1
chickenpox (1) 1
chickenpox - diagnosis (1) 1
chickenpox - epidemiology (1) 1
chickenpox - therapy (1) 1
chickenpox complications (1) 1
chickenpox vaccine (1) 1
children (1) 1
clinical medicine (1) 1
controlled release (1) 1
cpg islands (1) 1
crosslinking (1) 1
deoxyribonucleic acid--dna (1) 1
depotwirkung (1) 1
diagnostic (1) 1
diffusion (1) 1
diffusion barriers (1) 1
diffusionsbarriere (1) 1
disease (1) 1
diseases (1) 1
dna methylation (1) 1
drug delivery (1) 1
drug delivery systems (1) 1
drug therapy (1) 1
drug withdrawal (1) 1
drugs (1) 1
egfr (1) 1
epidemiology (1) 1
epigenetics (1) 1
equilibrium conditions (1) 1
fever (1) 1
fluorescence (1) 1
fluorescence microscopy (1) 1
funktionalisierung (1) 1
gefitinib (1) 1
gene expression (1) 1
gene regulation (1) 1
general & internal medicine (1) 1
genomes (1) 1
genomic imprinting (1) 1
hospitalization (1) 1
hospitalization - statistics & numerical data (1) 1
hydrogel (1) 1
hydrogels (1) 1
hydrothermales verfahren (1) 1
immunization (1) 1
immunotherapy (1) 1
impt1 (1) 1
infant (1) 1
infant, newborn (1) 1
infants (1) 1
intravenous administration (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 11/2019, Volume 381, Issue 21, pp. 2020 - 2031
Patients with advanced non–small-cell lung cancer with a PD-L1 expression level of 1% or more of tumor cells were randomly assigned to receive nivolumab plus... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antineoplastic Agents, Immunological - administration & dosage | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Lung Neoplasms - metabolism | Middle Aged | Carcinoma, Non-Small-Cell Lung - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Ipilimumab - adverse effects | Nivolumab - adverse effects | Carcinoma, Non-Small-Cell Lung - mortality | Antineoplastic Agents, Immunological - adverse effects | B7-H1 Antigen - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Ipilimumab - administration & dosage | Nivolumab - administration & dosage | Lung cancer, Non-small cell | Drug therapy | Patient outcomes | Ipilimumab | Testing | Small cell lung carcinoma | Lung cancer | Non-small cell lung carcinoma | Oncology | Cancer therapies | Chemotherapy | Immunotherapy | PD-L1 protein | Biomarkers | Clinical medicine | Mutation | Drug dosages | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus | B7-H1 Antigen | Carcinoma, Non-Small-Cell Lung | Antineoplastic Combined Chemotherapy Protocols | Cellular Biology | Lung Neoplasms | Life Sciences | Antineoplastic Agents, Immunological | Nivolumab
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 05/2020, Volume 38, Issue 15_suppl, pp. e21555 - e21555
e21555 Background: Lung-ONE study aims to determine the clinical utility in making decisions on planned 2nd line therapy in advanced NSCLC based on a... 
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 05/2020, Volume 38, Issue 15_suppl, pp. 9069 - 9069
9069 Background: Most patients with extensive SCLC develop drug resistance to platinum-based 1L therapy or discontinue for other reasons, and second-line (2L)... 
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 05/2020, Volume 38, Issue 15_suppl, pp. TPS9081 - TPS9081
TPS9081 Background: Although small cell lung cancer (SCLC) is often sensitive to established first-line therapies, many patients relapse and develop drug... 
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 05/2020, Volume 38, Issue 15_suppl, pp. 9500 - 9500
9500 Background: In the phase 3 CheckMate 227 Part 1 (NCT02477826; minimum follow-up, 29.3 mo), 1L NIVO + IPI significantly improved overall survival (OS) vs... 
Journal Article
Lung cancer (Amsterdam, Netherlands), ISSN 0169-5002, 12/2020, Volume 150, pp. 62 - 69
•A phase II randomized study of gefitinib versus gefitinib plus olaparib in 182 EGFR-mutation positive NSCLC patients.•The study included patients from Spain... 
Non-small-cell lung cancer | Olaparib | Gefitinib | EGFR | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 8562 - 8562
8562 Background: Nal-IRI is investigated as monotherapy in patients with SCLC who progressed on or after platinum regimen. The RESILIENT study is a Part 1... 
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 01/2014, Volume 32, Issue 3_suppl, pp. 665 - 665
665 Background: Bevacizumab, a humanized antibody against the molecular target endotelial growth factor VEGF-A, has incorporated to the standard of care of... 
Journal Article
Cancers, 08/2020, Volume 12, Issue 8
Genomic imprinting is a process that involves one gene copy turned-off in a parent-of-origin-dependent manner. The regulation of imprinted genes is broadly... 
Life Sciences & Biomedicine | Oncology | Science & Technology
Journal Article
El Mundo, ISSN 1134-4261, 04/2011
Newspaper Article
Revista internacional de sociología, ISSN 0034-9712, 05/1996, pp. 245 - 259
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.